Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Interest Expense

Last Annual Value

2.50M

3-Year CAGR

132%

5-Year CAGR

86%

10-Year CAGR

36%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Interest Expense

NTHI · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.50M
-2.8%85.9%N/A 
16.59M
84.9%203.9%N/A
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
0.00
N/AN/AN/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.15M
N/A4.4%N/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35